Kurs
-0,28%
Kurs
-0,28%
Open
35,40
High
35,40
Low
35,00
Close
35,00
Kursutveckling under dagen för detta pressmeddelande
(NOK).
Kalender
| Tid* | ||
| 2022-01-26 | - | Bokslutskommuniké 2021 |
| 2021-07-14 | - | Kvartalsrapport 2021-Q2 |
| 2021-06-30 | - | Årsstämma |
| 2021-05-27 | - | X-dag ordinarie utdelning NATTO 0.00 NOK |
| 2021-02-17 | - | Bokslutskommuniké 2020 |
| 2020-11-11 | - | Kvartalsrapport 2020-Q3 |
| 2020-07-15 | - | Kvartalsrapport 2020-Q2 |
| 2020-06-22 | - | X-dag ordinarie utdelning NATTO 0.00 NOK |
| 2020-06-19 | - | Årsstämma |
| 2020-05-06 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-19 | - | Bokslutskommuniké 2019 |
| 2019-11-13 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-21 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-31 | - | X-dag ordinarie utdelning NATTO 0.00 NOK |
| 2019-05-29 | - | Årsstämma |
| 2019-04-30 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-13 | - | Bokslutskommuniké 2018 |
| 2018-08-22 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-31 | - | X-dag ordinarie utdelning NATTO 0.00 NOK |
| 2018-05-30 | - | Årsstämma |
| 2018-02-08 | - | Bokslutskommuniké 2017 |
| 2017-11-24 | - | Extra Bolagsstämma 2017 |
| 2017-08-16 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-16 | - | X-dag ordinarie utdelning NATTO 0.00 NOK |
| 2017-05-15 | - | Årsstämma |
| 2017-05-15 | - | Kapitalmarknadsdag 2017 |
| 2017-05-15 | - | Kvartalsrapport 2017-Q1 |
| 2017-02-08 | - | Bokslutskommuniké 2016 |
| 2016-11-16 | - | Kvartalsrapport 2016-Q3 |
| 2016-08-17 | - | Kvartalsrapport 2016-Q2 |
| 2016-05-20 | - | Årsstämma |
| 2016-05-20 | - | Kvartalsrapport 2016-Q1 |
| 2016-02-26 | - | Bokslutskommuniké 2015 |
| 2015-11-25 | - | Kvartalsrapport 2015-Q3 |
| 2015-08-26 | - | Kvartalsrapport 2015-Q2 |
| 2014-11-26 | - | Kvartalsrapport 2014-Q3 |
| 2014-08-27 | - | Kvartalsrapport 2014-Q2 |
| 2014-05-27 | - | Kvartalsrapport 2014-Q1 |
| 2014-02-17 | - | Bokslutskommuniké 2013 |
| 2013-11-26 | - | Kvartalsrapport 2013-Q3 |
| 2013-08-27 | - | Kvartalsrapport 2013-Q2 |
| 2013-05-22 | - | Kvartalsrapport 2013-Q1 |
| 2013-02-28 | - | Bokslutskommuniké 2012 |
| 2012-11-15 | - | Kvartalsrapport 2012-Q3 |
| 2012-08-21 | - | Kvartalsrapport 2012-Q2 |
| 2012-05-16 | - | Kvartalsrapport 2012-Q1 |
| 2012-02-28 | - | Bokslutskommuniké 2011 |
| 2012-02-13 | - | Extra Bolagsstämma 2012 |
| 2011-11-17 | - | Kvartalsrapport 2011-Q3 |
| 2011-10-31 | - | Extra Bolagsstämma 2011 |
| 2011-08-18 | - | Kvartalsrapport 2011-Q2 |
| 2011-05-19 | - | Kvartalsrapport 2011-Q1 |
| 2011-02-25 | - | Bokslutskommuniké 2010 |
Beskrivning
| Land | Norge |
|---|---|
| Lista | OAX Equities |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
2021-05-12 08:30:16
Oslo, Norway (12 May 2021)
NattoPharma reports revenues of NOK 49.9 million for the quarter, a decrease of
11% compared to the same quarter last year. Underlying volumes decreased by 7%.
YTD Adjusted EBITDA came in at NOK 11.0 million, equal to a margin of 21.9%.
Performance highlights for Q1 2021 (Q1 2020 in brackets)
· Operating revenue of NOK 49.9m (NOK 56.3m)
· Adjusted EBITDA of NOK 11.0m (NOK 10.5m)
· Adjusted EBITDA margin of 21.9% (18.7%)
· Our supply situation, including Natural supply from India, is flowing as
normal, with no current delays despite COVID-19
CEO, Kjetil Ramsøy:
"The first quarter topline performance is in line with our expectations albeit
lower than Q1 2020 which was heavily impacted by both the start of the pandemic
last year and a very strong USD. It is gratifying to see that our profitability
is at an Adj. EBITDA of nearly 22% in the quarter, creating a solid basis for
achieving our full-year guiding. During Q1 we continued to build our inventory
position and maintained a strong focus on our working capital to ensure we can
meet the growth expectations in 2021."
Acquisition by Lesaffre
On 20 April 2021 Lesaffre announced the launch of their mandatory offer on
NattoPharma ASA and the offer is expected to conclude on May 18, 2021. More
information will be available when the mandatory offer has been completed.
For more information, please contact:
Robert Schrama, CFO, NattoPharma, robert.schrama@nattopharma.com
This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.